A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience

@article{Negro2015ATY,
  title={A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience},
  author={A Negro and M. D. Del Curto and Luana Lionetto and Paolo Martelletti},
  journal={The Journal of Headache and Pain},
  year={2015},
  volume={17},
  pages={1-9}
}
The efficacy and safety of OnabotulinumtoxinA (BOTOX®) in adults with chronic migraine (CM) were demonstrated in the PREEMPT program. However, the dosage used in this study was flexible from 155 U to 195 U at the physician’s discretion. Therefore, the objective of this prospective study was to compare the efficacy and safety of OnabotulinumtoxinA 195 U vs. 155 U for the treatment of CM and medication overuse headache (MOH) during a 2-year period. We prospectively evaluated the mean reduction in… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 9 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 44 references

Similar Papers

Loading similar papers…